North Point Portfolio Managers Corp OH decreased its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 213,425 shares of the biopharmaceutical company’s stock after selling 4,657 shares during the period. Gilead Sciences makes up 3.5% of North Point Portfolio Managers Corp OH’s investment portfolio, making the stock its 5th largest position. North Point Portfolio Managers Corp OH’s holdings in Gilead Sciences were worth $17,804,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in GILD. CWM LLC increased its position in Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 17 shares during the period. Cypress Wealth Advisors LLC increased its position in Gilead Sciences by 1.4% in the first quarter. Cypress Wealth Advisors LLC now owns 3,875 shares of the biopharmaceutical company’s stock worth $356,000 after buying an additional 54 shares during the period. Carroll Financial Associates Inc. increased its position in Gilead Sciences by 1.2% in the second quarter. Carroll Financial Associates Inc. now owns 4,875 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 60 shares during the period. Mountain Pacific Investment Advisers Inc. ID increased its position in Gilead Sciences by 2.1% in the second quarter. Mountain Pacific Investment Advisers Inc. ID now owns 3,574 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 74 shares during the period. Finally, iAB Financial Bank increased its position in Gilead Sciences by 3.3% in the second quarter. iAB Financial Bank now owns 2,750 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 87 shares during the period. Hedge funds and other institutional investors own 77.93% of the company’s stock.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 2.21% on Tuesday, hitting $73.82. The stock had a trading volume of 11,892,516 shares. The firm has a 50 day moving average price of $78.79 and a 200 day moving average price of $84.83. Gilead Sciences Inc. has a one year low of $73.56 and a one year high of $111.11. The company has a market capitalization of $97.42 billion, a P/E ratio of 6.48 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping the consensus estimate of $3.02 by $0.06. The business had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. Gilead Sciences’s revenue was down 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.15 EPS. On average, equities research analysts predict that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 2.55%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s payout ratio is currently 16.56%.

A number of equities analysts have recently commented on GILD shares. Royal Bank Of Canada raised their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, October 3rd. Jefferies Group cut their price objective on Gilead Sciences from $93.00 to $91.00 and set a “hold” rating on the stock in a report on Wednesday, August 31st. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, September 26th. Piper Jaffray Cos. restated an “overweight” rating and issued a $108.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 31st. Finally, Leerink Swann set a $112.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, September 22nd. Ten investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $104.71.

In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of the company’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $79.81, for a total transaction of $159,620.00. Following the transaction, the executive vice president now owns 64,122 shares of the company’s stock, valued at approximately $5,117,576.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $77.48, for a total value of $7,748,000.00. Following the transaction, the insider now directly owns 3,287,810 shares in the company, valued at approximately $254,739,518.80. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.